ArticleMycopathologia2025
Fungal Infections in Transplant Recipients Pre- and Post-coronavirus Disease 2019: Results from a Single-Center Retrospective Cohort Study.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo investigate the incidence, subtypes, and pathogens of fungal infections in transplant recipients pre- and post-coronavirus disease 2019 (COVID-19) and their prognosis.
methodsData from transplant recipients with fungal infections treated at our hospital between January 2005 and April 2024 were collected. Pre- and post-COVID-19 data were compared.
resultsAmong 3,505 transplant recipients, 203 had fungal infections, mostly in hematopoietic stem cell recipients (178 cases, 8.4%). The pre-COVID-19 incidence of fungal infections was 5.0%, with a median time from transplantation to infection of 96.5 days. The post-COVID-19 incidence was 6.3%, with a median time of 92.5 days. Before the COVID-19 outbreak, invasive fungal infections were predominant, with Candida as the outbreak, Candida, Aspergillus, Pneumocystis jirovecii, and mixed infections became more common. In addition to the oral cavity and lungs, infection sites following the COVID-19 outbreak also included the skin, blood, and intestinal tract. Twenty-six patients were treated with monotherapy, 14 of whom were treated with voriconazole. Voriconazole, sulfamethoxazole, and caspofungin are typically used in combination or sequentially for treatment. At 180 days, 1.4% of transplant recipients were aggravated before the outbreak of COVID-19, with a mortality rate of 8.2%. The proportion of exacerbations after the outbreak was 3.1%, with a mortality rate of 6.9%.
conclusionsPost-COVID-19, transplant recipients exhibited increased fungal infection incidence, broader pathogen diversity, and more frequent exacerbations. However, this was not accompanied by an increase in mortality, likely reflect both enhanced clinical surveillance and SARS-CoV-2-specific biological effects, such as immune dysregulation, endothelial damage and microbiome alterations.
Indexed as
Identifiers
40447921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.